|

CAR-T cells Clinical Trials

8 actively recruiting trials

Also known as: CAR-T cells injection

Pipeline

Early 1: 1Phase 1: 4Phase 2: 1Phase 3: 1Phase 1/2: 1

Top Sponsors

Zhejiang University1
Tongji Hospital1
Suzhou Immunofoco Biotechnology Co., Ltd1
Shenzhen Geno-Immune Medical Institute1
Second Affiliated Hospital of Guangzhou Medical University1

Indications

Cancer8
B-Cell Non-Hodgkin Lymphoma3
Mesothelin1
Relapsed/Refractory B-cell Non-Hodgkin Lymphoma1
CAR T Cell Therapy1

Other8 trials

A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Phase 1

A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma ( CT1190B-CG11001 )

Phase 1

A Clinical Study Exploring CT1190B in the Treatment of Patients with Relapsed/refractory B-cell Non-Hodgkin Lymphoma

Phase 1

A Phase III Randomized Study in CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer Patients

Phase 3

A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological Malignancies

Early 1

Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma

Phase 1/2

Mesothelin/GPC3/GUCY2C-CAR-T Cells Against Cancers

Phase 1

To Evaluate Safety and Efficacy of Autologous CD19 Chimeric Antigen Receptor (CAR)-T Cells in Relapsed/Refractory B- Non-Hodgkin Lymphoma (B-NHL)

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.